文献速递淋巴瘤浆细胞疾病

非华氏巨球蛋白血症型淋巴浆细胞淋巴瘤的临床特征与结局:一项瑞典淋巴瘤登记研究

Clinical characteristic and outcome of lymphoplasmacytic lymphoma of non-Waldenstrom macroglobulinemia type: A Swedish lymphoma registry study.
PubMed 文献 · Br J Haematol · 2021-12-27

基于瑞典淋巴瘤登记库2000年1月1日至2014年12月31日登记的1511例华氏巨球蛋白血症/淋巴浆细胞淋巴瘤患者,仅33例确诊为非华氏巨球蛋白血症型淋巴浆细胞淋巴瘤。其诊断时中位年龄69岁,多数可检出副蛋白(IgG 54%、IgA 15%),12%为非分泌型;与华氏巨球蛋白血症患者相比更年轻、诊断时不良预后因素更多(乳酸脱氢酶升高、贫血、淋巴细胞增多)、更常有症状并接受治疗,但两组总生存无显著差异(P=0.247),中位生存时间分别为71个月和96个月。

要点

  • 在1511例华氏巨球蛋白血症/淋巴浆细胞淋巴瘤登记患者中仅确认33例非华氏巨球蛋白血症型淋巴浆细胞淋巴瘤。
  • 非华氏巨球蛋白血症型患者诊断时中位年龄69岁,IgG副蛋白占54%、IgA占15%,12%为非分泌型。
  • 与华氏巨球蛋白血症相比,非华氏巨球蛋白血症型患者总生存无显著差异(P=0.247),中位生存71个月对96个月。

核心结论

  • 非华氏巨球蛋白血症型淋巴浆细胞淋巴瘤与华氏巨球蛋白血症在临床特征上存在差异,但两者生存无差异。

研究设计与样本

  • 基于瑞典淋巴瘤登记库的人群研究,纳入2000年1月1日至2014年12月31日登记的1511例华氏巨球蛋白血症/淋巴浆细胞淋巴瘤患者,其中仅33例确诊为非华氏巨球蛋白血症型淋巴浆细胞淋巴瘤。

主要发现

  • 非华氏巨球蛋白血症型淋巴浆细胞淋巴瘤患者诊断时中位年龄69岁,副蛋白以IgG为主(54%)、IgA占15%,12%为非分泌型。
  • 与华氏巨球蛋白血症患者相比,非华氏巨球蛋白血症型患者更年轻,诊断时不良预后因素更多,如乳酸脱氢酶升高、贫血和淋巴细胞增多。
  • 非华氏巨球蛋白血症型患者更常有症状并在诊断时接受治疗。
  • 非华氏巨球蛋白血症型与华氏巨球蛋白血症组总生存无显著差异(P=0.247),中位生存时间分别为71个月和96个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lymphoplasmacytic lymphoma (LPL) not fulfilling the WHO diagnostic criteria (2017) for Waldenstrom's macroglobulinemia (WM) (named non-WM LPL) is a rare disease and only a few systematic studies have been published. Here, we present a population-based study of non-WM LPL focusing on diagnostic difficulties, patient characteristics, and outcome. From 1511 patients included in the Swedish Lymphoma Registry 1 Jan 2000 - 31 Dec 2014 with a diagnosis of WM/LPL, we could confirm the diagnosis of non-WM LP in only 33 patients. The median age at diagnosis was 69 years. A paraprotein was found in most (IgG in 54%, IgA in 15%) and 12% of the cases were non-secretory. Compared with the WM patients, the non-WM LPL patients were younger, had more adverse prognostic factors such as elevated LDH, anaemia, and lymphocytosis at diagnosis. In addition, the non-WM LPL patients more often were symptomatic and received treatment at diagnosis. The overall survival (OS) did not significantly differ between the non-WM LPL and WM groups (P = 0.247), with a median survival time of 71 and 96 months, respectively. To conclude, we found differences in clinical features between WM and non-WM LPL, but no difference in survival.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Brandefors L, Sander B, Lundqvist K, et al. Clinical characteristic and outcome of lymphoplasmacytic lymphoma of non-Waldenstrom macroglobulinemia type: A Swedish lymphoma registry study. Br J Haematol. 2021. PMID: 34959252. doi:10.1111/bjh.18002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。